Findings from clinical trials of proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors have led to concern that these drugs or the low levels of low-density lipoprotein (LDL) cholesterol ...
Correspondence to Joseph Michael Northey, Joseph Northey, University of Canberra Research Institute for Sport and Exercise, Building 29, University Drive, Bruce ACT, 2617, Australia; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results